Martindale Pharma, the UK-based leading international specialty pharmaceutical company, has announced the relaunch of its methadone oral solution product in Scandinavia via its strategic partner Unimedic AB. Martindale Pharma’s methadone oral solution will be available for distribution in Sweden, Norway, and Denmark, providing a critical treatment option for opioid dependence and pain management.
The reintroduction of the methadone range addresses a growing need for consistent access to high-quality, licensed opioid substitution therapies across the region. With a strong track record in the production of controlled drugs and addiction therapies, Martindale Pharma aims to support healthcare providers in delivering safe and effective treatment.
Unimedic AB, a trusted pharmaceutical distributor in the Nordic region, will oversee local distribution and ensure compliance with national healthcare regulations. The partnership underscores a shared commitment to improving patient outcomes and reinforcing the continuity of care for individuals undergoing opioid substitution treatment.
Martindale Pharma’s methadone oral solution is manufactured under stringent quality standards in the UK and will be offered in a range of concentrations tailored to clinical needs. The relaunch is part of Martindale’s broader strategy to expand access to essential medicines in international markets.